BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Obrixtamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Obrixtamig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05963867-7739@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Obrixtamig: Phase 1 readout est. (NCT05963867)
DESCRIPTION:Obrixtamig\, phase 1\, Small Cell Lung Cancer.\nStudy: A Study 
 to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lun
 g Cancer or Neuroendocrine Cancer\nEstimated primary completion: 15 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/obrixtamig#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05963
 867
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05990738-7739@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Obrixtamig: Phase 1 readout est. (NCT05990738)
DESCRIPTION:Obrixtamig\, phase 1\, Small Cell Lung Cancer.\nStudy: DAREON
 ™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated
  by People With Small Cell Lung Cancer When Taken Together With a Single A
 gent Chemotherapy\nEstimated primary completion: 30 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/obrixtamig#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05990738
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06077500-7739@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Obrixtamig: Phase 1 readout est. (NCT06077500)
DESCRIPTION:Obrixtamig\, phase 1\, Small Cell Lung Cancer.\nStudy: DAREON
 ᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Additio
 n to Standard of Care Are Tolerated by People With Advanced Small Cell Lun
 g Cancer\nEstimated primary completion: 31 March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/obrixtamig#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06077500
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05916313-7739@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20270809
DTEND;VALUE=DATE:20270810
SUMMARY:Obrixtamig: Phase 1 readout est. (NCT05916313)
DESCRIPTION:Obrixtamig\, phase 1.\nStudy: A Study to Test How Well Differen
 t Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain Th
 at is Positive for DLL3\nEstimated primary completion: 9 August 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/obrixtamig#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05916313
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132113-7739@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Obrixtamig: Phase 1 readout est. (NCT06132113)
DESCRIPTION:Obrixtamig\, phase 1.\nStudy: DAREON™-7: A Study to Test How 
 Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerate
 d by People With Advanced Neuroendocrine Cancers\nEstimated primary comple
 tion: 9 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /obrixtamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06132113
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05882058-7739@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20271217
DTEND;VALUE=DATE:20271218
SUMMARY:Obrixtamig: Phase 2 readout est. (NCT05882058)
DESCRIPTION:Obrixtamig\, phase 2\, Small Cell Lung Cancer.\nStudy: DAREON
 ™-5: A Study to Test Whether Different Doses of BI 764532 Help People Wi
 th Small Cell Lung Cancer or Other Neuroendocrine Cancers\nEstimated prima
 ry completion: 17 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/obrixtamig#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05882058
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07929051-7739@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20280703
DTEND;VALUE=DATE:20280704
SUMMARY:Obrixtamig: Phase 3 readout est. (NCT07929051)
DESCRIPTION:Obrixtamig\, phase 3.\nStudy: A Study to Test Obrixtamig Treatm
 ent in People With Different Types of Advanced Cancer Who Took Part in a P
 revious Study With Obrixtamig\nEstimated primary completion: 3 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/obrixtamig#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07929051
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472517-7739@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20280909
DTEND;VALUE=DATE:20280910
SUMMARY:Obrixtamig: Phase 3 readout est. (NCT07472517)
DESCRIPTION:Obrixtamig\, phase 3\, Small Cell Lung Cancer.\nStudy: DAREON 
 ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Comp
 are Obrixtamig Plus Atezolizumab\, Carboplatin\, and Etoposide Treatment W
 ith Standard Chemoimmunotherapy\nEstimated primary completion: 9 September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/obrixtamig#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0747251
 7
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07544654-7739@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20291213
DTEND;VALUE=DATE:20291214
SUMMARY:Obrixtamig: Phase 3 readout est. (NCT07544654)
DESCRIPTION:Obrixtamig\, phase 3.\nStudy: DAREON®-NEC-1: A Study in People
  With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obr
 ixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherap
 y\nEstimated primary completion: 13 December 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/obrixtamig#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07544654
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843940-7739@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20300417
DTEND;VALUE=DATE:20300418
SUMMARY:Obrixtamig: Phase 1/2 readout est. (NCT07843940)
DESCRIPTION:Obrixtamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Test Obrixtamig in Combination With Pumitamig in People With Advanced
  Small Cell Lung Cancer (Dareon®-Rosetta35)\nEstimated primary completion
 : 17 April 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obri
 xtamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07843940
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07707895-7739@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20300426
DTEND;VALUE=DATE:20300427
SUMMARY:Obrixtamig: Phase 1/2 readout est. (NCT07707895)
DESCRIPTION:Obrixtamig\, phase 1/2\, Small Cell Lung Cancer.\nStudy: DAREON
 ®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People Wi
 th Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers\nEstima
 ted primary completion: 26 April 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/obrixtamig#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07707895
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07561645-7739@assetmemo.bio
DTSTAMP:20261121T005821Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Obrixtamig: Phase 2 readout est. (NCT07561645)
DESCRIPTION:Obrixtamig\, phase 2.\nStudy: A Trial for the Treatment of Adva
 nced Large-Cell Neuroendocrine Cancer of the Lung\nEstimated primary compl
 etion: April 2032. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ob
 rixtamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07561645
URL:https://assetmemo.bio/drug/obrixtamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
